Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

Conference proceeding

P Mease, P S Helliwell, D Gladman, D Poddubnyy, X Baraliakos, S Chakravarty, A Kollmeier, X Xu, S Sheng, S Xu, …

Sep 2021

Additional Links

13 Record Views

1 citations in Scopus

Title: Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Creators: P Mease
P S Helliwell
D Gladman
D Poddubnyy
X Baraliakos
S Chakravarty
A Kollmeier
X Xu
S Sheng
S Xu
M Shawi
D van der Heijde
A Deodhar
Publisher: Wiley
Resource Type: Conference proceeding
Language: English
Academic Unit: Rheumatology
Scopus ID: 2-s2.0-85123662864
Other Identifier: 991019170329704721